perfusion of Exacyl

Phase 2Small molecule

CCentre Hospitalier Universitaire de Saint Etienne

perfusion of Exacyl is one of 39 small molecule programs targeting Total Hip Arthroplasty. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Hip ArthroplastyActive, not recruiting

Total Hip ArthroplastyPhase 2

Active, not recruiting

Competition

Competitive Landscape

101 competitors in Total Hip Arthroplasty

#DrugCompanyPhaseTrials

Toradol

Roche

Approved

1 2

Naropin

FFresenius Kabi Oncology Ltd.

Approved

9 3

Zometa

Pfizer

Approved

1 4

Medrol

Pfizer

Approved

1 5

Marcaine

IInnocoll

Approved

5 6

Decadron

AAspen Global Incorporated

Approved

5 7

Xylocaine

MMEDRx USA, Inc.

Approved

4 8

Oxycontin

PProtega

Approved

1 9

Advil

KKenvue Brands

Approved

1 10

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Total Hip Arthroplasty1 trial

A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty

Completed·—·Phase 2·NCT03822793·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for perfusion of Exacyl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — perfusion of Exacyl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for perfusion of Exacyl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire de Saint Etienne company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCentre Hospitalier Universitaire de Saint Etienne

perfusion of Exacyl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Total Hip Arthroplasty1 trial

References

Drug Info

Quick Facts

Related News